Indications for use:
Non-specific ulcerative colitis (chronic inflammation of the colon with the formation of ulcers caused by unknown causes), also in diseases that occur with autoimmune disorders (disorders based on allergic reactions to the body’s own tissues or waste products), including as a basic tool in the treatment of rheumatoid arthritis (an infectious-allergic disease from the group of collagenoses, characterized by chronic progressive inflammation of the joints).
Salazopyridazinum (Salazopyridazine) method of administration and doses:
In ulcerative colitis, salazopyridazine is prescribed for adults inside (after eating) in tablets of 0.5 g 4 times every day for 3-4 weeks. If during this period a therapeutic effect is manifested, the daily dose is reduced to 1.0-1.5 g (0.5 g 2-3 times every day) and treatment is continued for another 2-3 weeks. If there is no effect, the drug is stopped. Patients with mild forms of the disease are prescribed the product first at a daily dose of 1.5 g, and if there is no effect, the dose is increased to 2 g per day.
For children aged 3 to 5 years, salazopyridazine is prescribed, starting with a dose of 0.5 g per day (2-3 doses). In the absence of effect for 2 weeks. the product is canceled, and if there is a therapeutic effect, treatment is continued at this dose for 5-7 days, then the dose is reduced by 2 times and treatment is continued for another 2 weeks. In the case of clinical remission (temporary weakening or disappearance of the manifestations of the disease), the daily dose is again halved and prescribed until the 40-50th day, counting from the start of treatment.
Children aged 5 to 7 years are prescribed the product, starting from 0.75-1.0 g per day; from 7 to 15 years – with a dose of 1.0-1.2-1.5 g per day. Treatment and dose reduction are carried out according to the same scheme as in children from 3 to 5 years.
The use of salazopyridazine is combined with general treatments and diet recommended for ulcerative colitis.
Salazopyridazine can also be used for ulcerative colitis and Crohn’s disease (a disease of unknown cause, characterized by inflammation and narrowing of the lumen of certain sections of the intestine) rectally (into the rectum) in the form of suspensions (suspension of solid particles in a liquid) and suppositories.
Suspension of salazopyridazine 5% is used for rectal administration with damage to the rectum and sieve, in the preoperative period and after subtogal colectomy (after removal of part of the colon), with poor tolerability of the product in the form of tablets. The suspension is slightly heated and injected as an enema into the rectum or into the stump of the intestine, 20-40 ml 1-2 times a day. Children are injected with 10-20 ml (depending on age). Rectal administration can be combined with ingestion of the substance.
Candles are used rectally. In the acute stage of the disease, 1 suppository is prescribed 2-4 times every day for 2 weeks. up to 3 months The duration of the course depends on the effectiveness of the treatment and the tolerability of the product. The maximum daily dose is 4 suppositories (2 g). At the same time, you can take salazopyridazine tablets (not exceeding a total daily dose of 3 g) and other drugs for the treatment of ulcerative colitis.
In order to prevent relapses (reappearance of signs of the disease), 1-2 suppositories are prescribed per day for 2-3 months.
Doses and regimen of the drug in other forms of colitis with ulcerative lesions are the same as in non-specific ulcerative colitis.
Salazopyridazinum (Salazopyridazine) contraindications:
The drug is contraindicated in the presence of a history (medical history) of data on toxic-allergic reactions in the treatment of sulfonamides and salicylates.
Salazopyridazinum (Salazopyridazine) side effects:
When taking salazopyridazine tablets orally, the same adverse reactions are possible as with the use of sulfonamides and salicylates: allergic phenomena, leukopenia (decrease in the level of leukocytes in the blood), dyspeptic disorders (digestive disorders), sometimes a non-cardinal decrease in hemoglobin levels (the functional structure of an erythrocyte that ensures its interaction with oxygen). In such cases, the dose should be reduced or the product discontinued. After the introduction of the suspension, a burning sensation in the rectum and the urge to defecate (empty bowel) may appear, especially with rapid administration. When using salazopyridazine in suppositories, there may be a burning sensation and soreness in the rectum, sometimes an increase in stool.
Before using the medication“Salazopyridazinum (Salazopyridazine)” should be consulted with a doctor.
The instructions are provided solely for familiarization with “Salazopyridazinum (Salazopyridazine) “.